Targeting DNA Damage Response genes with oligonucleotides for therapeutic modulation of HTT somatic instability

You are now leaving www.triplettx.com, a website provided by Triplet Therapeutics, Inc. The content displayed on external websites is not controlled by Triplet Therapeutics, Inc., and Triplet Therapeutics, Inc. assumes no responsibility for the information or statements on such external websites.